Scarica l'app Stockscreener
36.46
1.67%
0.60
Dopo l'orario di chiusura:
35.75
-0.71
-1.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$35.86
Aprire:
$36.02
Volume 24 ore:
5.23M
Relative Volume:
1.41
Capitalizzazione di mercato:
$15.76B
Reddito:
$2.26B
Utile/perdita netta:
$1.09B
Rapporto P/E:
15.56
EPS:
2.3431
Flusso di cassa netto:
$2.70B
1 W Prestazione:
-1.78%
1M Prestazione:
+1.73%
6M Prestazione:
+12.32%
1 anno Prestazione:
+35.74%
Intervallo 1D:
$35.88
$36.78
Intervallo di 1 settimana:
$35.80
$37.97
Portata 52W:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Confronta RPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.46 | 15.50B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Royalty Pharma lead independent director Fernandez steps down By Investing.com - Investing.com Nigeria
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - The Manila Times
Henry Fernandez steps down from Royalty Pharma board - StreetInsider
Royalty Pharma's Lead Independent Director Exits Following Successful Post-IPO Growth Period - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Raised to Buy at Wall Street Zen - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 55,400 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Ex-Dividend Reminder: Eli Lilly, Teleflex and Royalty Pharma - Nasdaq
Forsta AP Fonden Sells 169,100 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Swiss National Bank Trims Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma plc a potential multi baggerGlobal Markets & Fast Gaining Stock Reports - kangso.co.kr
Vanguard Group Inc. Sells 676,561 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - Insider Monkey
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments - Yahoo Finance
Cary Street Partners Financial LLC Makes New Investment in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Director Norden Gregory Sells 33,500 Shares at $36.23 on 8/11/2025 - AInvest
CenterBook Partners LP Sells 41,728 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model - MSN
Royalty Pharma PLC (NASDAQ:RPRX) Shares Bought by Koss Olinger Consulting LLC - MarketBeat
Did Rising Costs and Lower Margins Just Shift Royalty Pharma's (RPRX) Investment Narrative? - simplywall.st
Royalty Pharma: Keep Delivering, Buy Confirmed (NASDAQ:RPRX) - Seeking Alpha
Royalty Pharma’s Earnings Call Highlights Strong Growth and Strategic Moves - The Globe and Mail
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's Why - MarketBeat
More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream - insights.citeline.com
UBS Adjusts Price Target on Royalty Pharma to $37 From $36, Maintains Neutral Rating - MarketScreener
Royalty Pharma plc (NASDAQ:RPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
PTC Therapeutics Earnings Preview: Analysts Expect $-1.07 EPS, Historical Performance and Stock Performance - AInvest
Royalty Pharma Reports Strong Q2 2025 Results - TipRanks
Royalty Pharma (RPRX) Q2 Receipts Up 20% - Mitrade
Royalty Pharma Plc Q2 Income Retreats - Nasdaq
Royalty Pharma Raises 2025 Portfolio Receipts Guidance to $3.05B-$3.15B, Achieving 20% Growth in Top Line - AInvest
Royalty Management Holding Corporation shares rise 5.65% intraday after Royalty Pharma plc reports Q2 2025 results. - AInvest
Royalty Pharma stock price target raised to $48 from $42 at BofA Securities - Investing.com UK
Royalty Pharma Q2 2025 Earnings Call Transcript - MarketBeat
Royalty Pharma (RPRX) PT Raised to $48 at BofA Securities - StreetInsider
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates - sharewise.com
Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth By Investing.com - Investing.com Australia
Royalty Pharma earnings missed by $0.99, revenue fell short of estimates - Investing.com Nigeria
Royalty Pharma plc SEC 10-Q Report - TradingView
Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth - Investing.com
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings - Yahoo Finance
Transcript : Royalty Pharma plc, Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Royalty Pharma reports second quarter 2025 results - MarketScreener
Royalty Pharma Q2 2025 slides: Double-digit growth and raised guidance By Investing.com - Investing.com South Africa
Royalty Pharma Q2 2025 slides: Double-digit growth and raised guidance - Investing.com India
Royalty Pharma Q2 Net Income Falls, Revenue Rises - MarketScreener
Royalty Pharma Reports Second Quarter 2025 Results - TradingView
Earnings Flash (RPRX) Royalty Pharma plc Reports Q2 Revenue $579.0M - MarketScreener
53,119 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by XTX Topco Ltd - MarketBeat
Mackenzie Financial Corp Purchases 205,356 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
HB Wealth Management LLC Invests $392,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma stock hits 52-week high at 37.91 USD - Investing.com
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):